DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-2.73%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.75B
AUM Growth
+$4.75B
(+6.2%)
Cap. Flow
+$377M
Cap. Flow
% of AUM
7.95%
Top 10 Holdings %
Top 10 Hldgs %
38.71%
Holding
141
New
13
Increased
21
Reduced
12
Closed
13
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$52M |
| 2 |
Gilead Sciences
GILD
|
$48.7M |
| 3 |
Cogent Biosciences
COGT
|
$38.6M |
| 4 |
Merus
MRUS
|
$35.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$34.6M |
Top Sells
| 1 |
Kura Oncology
KURA
|
$32.8M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$22.2M |
| 3 |
Organogenesis Holdings
ORGO
|
$19.6M |
| 4 |
GoodRx Holdings
GDRX
|
$18.9M |
| 5 |
Nuvation Bio
NUVB
|
$18.8M |
Sector Composition
| 1 | Healthcare | 52.41% |
| 2 | Financials | 1.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
101
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-249,988
| Closed | -$14.1M |
|
102
PMV Pharmaceuticals
PMVP
$82.1M
| – | – |
-470
| Closed | -$10K |
|
|
103
Nuvation Bio
NUVB
$1.08B
| – | – |
-3,577,233
| Closed | -$18.8M |
|
104
KalVista Pharmaceuticals
KALV
$713M
| – | – |
-830,472
| Closed | -$12.2M |
|
|
105
GoodRx Holdings
GDRX
$1.49B
| – | – |
-979,106
| Closed | -$18.9M |
|
106
Cullinan Oncology
CGEM
$456M
| – | – |
-375,585
| Closed | -$3.93M |
|
107
Biogen
BIIB
$20.8B
| – | – |
0
| – | – |
|
108
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-1,012,000
| Closed | -$16.5M |
|
109
BioAtla
BCAB
$28.7M
| – | – |
-289,002
| Closed | -$1.45M |
|
110
American Well
AMWL
$112M
| – | – |
-391,115
| Closed | -$1.65M |
|